Last reviewed · How we verify
NCT05652179
SGB Reduces the Incidence and Severity of CSA-AKI
NA trial testing Stellate ganglion block in Stellate Ganglion Block in 396 participants. Completed in 30 December 2023.
1 December 2023
Quick facts
| Lead sponsor | Yangzhou University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 396 |
| Start date | 10 January 2023 |
| Primary completion | 1 December 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Stellate ganglion block — full drug profile →
Conditions studied
- Stellate Ganglion Block — all drugs for Stellate Ganglion Block →
Sponsor
Yangzhou University
Who can join
Adults 18 to 80, any sex, with Stellate Ganglion Block. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of acute kidney injury after cardiopulmonary bypass cardiac surgery is high, which increases postoperative mortality and is not conducive to the prognosis of patients. Stellate ganglion blocks increase renal blood flow, reduce inflammation and stress, and protect the heart muscle. In this study, stellate ganglion block was used to promote rapid recovery of kidney function after cardiopulmonary bypass cardiac surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preemptive left stellate ganglion block reduces the incidence and severity of cardiac surgery-associated acute kidney injury: a randomized clinical trial.
Zhou W, Yu Y, Tian S, Wu H, et al · · 2025 · cited 2× · PMID 40643258 · DOI 10.1097/js9.0000000000002913
Verify or expand the search:
- PubMed search for NCT05652179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stellate ganglion block
Trials testing the same drug.
- NCT06354673 — Stellate Ganglion Block Combined With Dexmedetomidine or Subanesthetic Ketamine Infusion for Treatment of Neurostorm. · NA · completed
- NCT06319534 — Stellate Ganglion Block in Bulbar Palsy · NA · completed
- NCT06300658 — Stellate Ganglion Block for Preserving Arteriovenous Fistula in Hemodialysis Patients Undergoing Major Lower Limb Orthop · NA · unknown
- NCT06265792 — Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea · NA · unknown
- NCT06228157 — Efficacy of Stellate Ganglion Block in Children With Autistic Disorder · NA · withdrawn
Other recruiting trials for Stellate Ganglion Block
Currently open trials in the same condition.
- NCT07129811 — Stellate Ganglion Block in Complex Regional Pain Syndrome · NA · recruiting
- NCT06815887 — Adding Magnesium Sulfate to Local Anesthetic in Combined Pectoral Nerve and Stellate Ganglion Block for Postoperative Pa · NA · recruiting
Other Yangzhou University trials
Trials by the same sponsor.
- NCT06517069 — Effect of TEAS Combined With Oxycodone on Postoperative Visceral Pain in Gynecologic Laparoscopic Patients · NA · recruiting
- NCT05936918 — Application of Transcutaneous Electrical Acupoint Stimulation in Laparoscopic Cholecystectomy · NA · unknown
- NCT05909696 — Median Effective Dose of Rocuronium for the Prevention of Myofibrillation Caused by the Injection of Succinylcholine · NA · completed
- NCT06456710 — Effect of a Psychological Intervention on Stigma: a Randomized Controlled Study · NA · completed
- NCT05932485 — Effect of Stellate Ganglion Block on New Atrial Fibrillation After Coronary Artery Bypass Grafting · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05652179 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yangzhou University
- Last refreshed: 23 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05652179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing